* article"Starpharma’s study results...

* article

"Starpharma’s study results encouraging

Starpharma (ASX:SPL) rose by over 10% this morning after reporting that DEP HER2-zirconium, its radiodiagnostic candidate, has demonstrated imaging benefits in just-completed study results.

DEP HER2-zirconium showed a favourable biodistribution profile, with excellent imaging contrast between tumour and normal tissues. The result also indicated rapid uptake and high levels of tumour accumulation in a HER+ breast cancer model.

The results are very encouraging as they confirm the binding properties of DEP HER2-zirconium, and support a precision medicine approach for cancer patients.

Starpharma is currently developing the DEP HER2-zirconium designed to diagnose, stage, and monitor HER2-positive (HER2+) cancers with improved sensitivity.

“Radiotheranostics and HER2 therapeutics are both rapidly growing categories, with a number of highly successful product launches in recent years,” said Starpharma CEO, Jackie Fairley.

“The application of Starpharma’s DEP technology in the radiotheranostic area presents a substantial opportunity to expand the commercial opportunity for DEP.”

Meanwhile, the company also has a flagship product already in the market called Viraleze, a nasal spray that contains an antimicrobial/anti-infective polylysine dendrimer called SPL7013.

One key advantage of Viraleze nasal spray is its broad-spectrum antiviral activity, which makes it a promising tool for pandemic preparedness strategies or the emergence of as-yet-unknown viruses"